JPRN-UMIN000025808尚未招募未知
Efficacy and safety of luseogliflozin in patient with type 2 diabetes complicated with hepatic dysfunction - Efficacy and safety of luseogliflozin in patient with type 2 diabetes complicated with hepatic dysfunction
Seino Internal Medicine Clinic0 个研究点目标入组 50 人开始时间: 2017年1月23日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Type 1 diabetes 2) Has history of severe ketosis, diabetic coma, or precoma 3) With severe infection, pre or post surgery, and serious trauma 4) With severe renal dysfunction (eGFR<30 mL/min/1.73m2) 5) Has stroke, myocardial infarction, or other serious cardiovascular complications requiring hospitalization within 6 months 6) Receiving SGLT2 inhibitor 7) Nursing or pregnant or planning to become pregnant 8) Has hypersensitivity to luseogliflozin or any other excipients of luseogliflozin 9) Considered as inadequate by the investigator
研究者
相似试验
尚未招募
4 期
Efficacy and Safety of empagliflozin in patients with hepatic ascites: a randomized controlled trialDigestive SystemPACTR202402866059449one60
已完成
不适用
Efficacy and safety of Ipragliflozin in patients with type 2 diabetes who have inadequate glycemic control.Type 2 diabetesJPRN-UMIN000014306akakinen clinic100
进行中（未招募）
1 期
Safety and effect of treatment with the antidiabetic drug liraglutide in patients with type 2 diabetes and severely impaired kidney functio1) Patients with type 2 diabetes (T2D) and no or severely reduced kidney function, depending on chronic dialysis treatment. 2) Patients with T2D and normal kidney function.MedDRA version: 14.1Level: LLTClassification code 10012347Term: Dependence on renal dialysisSystem Organ Class: 10041244 - Social circumstancesMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 14.1Level: PTClassification code 10061835Term: Diabetic nephropathySystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2010-021922-36-DKDepartment of Nephrology, Rigshospitalet, University of Copenhagen
已完成
不适用
Evaluation of the efficacy and safety of luseogliflozin and changes in QOType 2 diabetes mellitusJPRN-UMIN000023035The Institute for Adult Diseases, Asahi Life Foundation64
已完成
不适用
Effective and safe examination of Luseogliflozin for patients with fatty liver merger type II diabetes mellitusfatty liver merger type II diabetes mellitusJPRN-UMIN000021087akakinen Clinic40